Clinical Impact of PET Imaging in Patients With Metastatic Prostate Cancer
- Resource Type
- Authors
- Murat Tuncel; Meltem Caglar Tuncali; Tuğçe Telli; Mustafa Erman
- Source
- Clinical Nuclear Medicine. 45:757-764
- Subject
- Male
medicine.medical_specialty
Abdominal ct
Sensitivity and Specificity
Neuroendocrine differentiation
030218 nuclear medicine & medical imaging
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Positron Emission Tomography Computed Tomography
medicine
Humans
Radiology, Nuclear Medicine and imaging
In patient
Neoplasm Metastasis
Radioactive Tracers
Aged
Cause of death
business.industry
Prostatic Neoplasms
Cancer
General Medicine
Pet imaging
medicine.disease
Clinical trial
030220 oncology & carcinogenesis
Radiology
business
- Language
- ISSN
- 1536-0229
0363-9762
Prostate cancer (Pca) is the most common cancer and the second leading cause of death among men. Although conventional bone scans and abdominal CT are preferred in most of the guidelines and clinical trials, PET/CT has already started to become the inevitable part of Pca management because of its higher sensitivity and specificity. Radiotracers used for PET imaging show different molecular aspects of the disease process. Although Ga-prostate-specific membrane antigen offers the highest sensitivity and specificity, other PET radiotracers such as F-FDG and Ga-DOTATATE still have a role in patients with prostate-specific membrane antigen-negative diseases such as Pca with neuroendocrine differentiation. In this pictorial essay, we have presented a series of patients with metastatic Pca who had PET images with different radiotracers and discussed the clinical role of this imaging modality in patient management.